<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366374">
  <stage>Registered</stage>
  <submitdate>13/01/2015</submitdate>
  <approvaldate>23/04/2015</approvaldate>
  <actrnumber>ACTRN12615000373572</actrnumber>
  <trial_identification>
    <studytitle>Effect of nebulized Budesonide on respiratory mechanics and oxygenation in patients with acute lung injury/acute respiratory distress syndrome: A prospective clinical study.</studytitle>
    <scientifictitle>Effect of nebulized budesonide on respiratory mechanics and oxygenation in patients with acute lung injury/acute respiratory distress syndrome(ALI/ARDS).</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute lung injury.</healthcondition>
    <healthcondition>Acute respiratory distress syndrome.</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Other anaesthesiology</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>60 patients admitted to the ICU due to ALI/ARDS assigned to two groups:budesonide group(30 patients)  where 1mg-2 ml budesonide suspension is nebulized through the endotracheal tube,while in the control group(30 patients) 2 ml isotonic saline is nebulized instead of budesonide.This regimen is applied twice daily for three successive days.Nebulization is performed using specific ventilator nebulized (Aeroneb pro-Aeroneb professional nebulized system Aerogen( Ireland) with an oxygen flow of 8 liters/ min. The duration of each Nebulization session is 15 minutes. before each session, recruitment manoeuvre is done by increasing peak airway so as to get a plateau pressure of 30 cm. H2o for 30 seconds.</interventions>
    <comparator>Nebulized budesonide is being compared to nebulized saline in patients with ALI/ARDS</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pao2/fio2  ; it is calculated from the measured Pao2 ( from arterial blood gas analysis) and the inspired oxygen concentration. Fio2  is the inspired fraction of oxygen given by anesthesiologist whether pure oxygen(i.e 100% oxygen) or in combination with air(e.g. 60% oxygen in 40% air).




</outcome>
      <timepoint>basal( before nebulization) and after termination of 6 nebulization sessions ( i.e after 72 hours) with either budesonide or isotonic saline.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Peak inspiratory pressure(PIP)- plateau pressure.
Both parameters are assessed from the screen of Binnette re spirometer.
</outcome>
      <timepoint>basal( before nebulization) and after termination of 6 nebulization sessions( i.e after 72 hours) with either budesonide or isotonic saline.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients should fulfill the criteria of ALI/ARDS according to 2012 Berlin definition of ALI/ARDS</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Refusal of consent by relatives,age &lt;18 or&gt;65 years,chronic obstructive pulmonary disears,restrictive respiratory insufficiency,increased intracranial pressure, bronchpleural fistula,acute myocardial infarction and neuromuscular disease.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/07/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>South valley university</primarysponsorname>
    <primarysponsoraddress>South valley university-Qena-postal code 85823</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>South valley university</fundingname>
      <fundingaddress>South valley university- Qena-postal code 85823</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Qena university hospital</sponsorname>
      <sponsoraddress>Qena university hospital-Qena-postal code 85823</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We want to study the effect of nebulized budesonide on oxygenation and respiratory mechanics when used in conjunction with recruitment maneuver in patients with ALI/ARDS</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics Committee of Qena university hospitals</ethicname>
      <ethicaddress>Qena-P.O.83523</ethicaddress>
      <ethicapprovaldate>3/01/2014</ethicapprovaldate>
      <hrec>Not changed</hrec>
      <ethicsubmitdate>4/12/2013</ethicsubmitdate>
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Hatem saber mohamed</name>
      <address>Qena university hospital -Qena- postal code 85823</address>
      <phone>+201005257062</phone>
      <fax />
      <email>dr.hatem_saber@hotmail.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Hatem saber mohamed</name>
      <address>Qena university hospital-Qena-postal code 85823</address>
      <phone>+201005257062</phone>
      <fax />
      <email>dr.hatem_saber@hotmail.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Salah mostafa asida</name>
      <address>Qena university hospital-Qena-postal code 85823</address>
      <phone>+201005262075</phone>
      <fax />
      <email>Salasida@hotmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Hatem saber mohamed</name>
      <address>Qena university hospital-Qena-postal code  85823</address>
      <phone />
      <fax />
      <email />
      <country>Egypt</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>